Hello Eire, please ask on my behalf a question concerning the mitral valve repair partnership that Anteris recently entered into with v2vmedtech inc. What deficiencies in the current mitral repair treatments from (Abbott and Edwards) is Anteris anticipating that their new device will overcome and be superior in performance to.
As a follow up to this question, please ask if Anteris will be forming an expert advisory board to this new mitral valve project and when does Mr Paterson anticipate that board will start taking shape.
Thank you.
AVR Price at posting:
$22.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)